SEC Form 4 · accession 0001192482-15-000200

COLLEGIUM PHARMACEUTICAL, INC · COLL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

May 12, 2015

Accepted (ET)

May 13, 2015 · 4:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001267565

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3	May 12, 2015	C	1,860,570	—	A	1,860,750	I	By Longitude Venture Partners, L.P.
Common Stock^F1,F3	May 12, 2015	C	458,102	—	A	2,318,672	I	By Longitude Venture Partners, L.P.
Common Stock^F1,F3	May 12, 2015	C	741,830	—	A	3,060,502	I	By Longitude Venture Partners, L.P.
Common Stock^F3	May 12, 2015	P	196,070	$12.00	A	3,256,572	I	By Longitude Venture Partners, L.P.
Common Stock^F1,F3	May 12, 2015	C	37,290	—	A	37,290	I	By Longitude Capital Associates, L.P.
Common Stock^F1,F3	May 12, 2015	C	9,182	—	A	46,472	I	By Longitude Capital Associates, L.P.
Common Stock^F1,F3	May 12, 2015	C	14,868	—	A	61,340	I	By Longitude Capital Associates, L.P.
Common Stock^F3	May 12, 2015	P	3,930	$12.00	A	65,270	I	By Longitude Capital Associates, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B Convertible Stock^F3,F1,F2	—	May 12, 2015	C	12,837,935	D	—	—	Common Stock	1,860,570	I
Series B Convertible Stock^F3,F1,F2	—	May 12, 2015	C	257,303	D	—	—	Common Stock	37,290	I
Series C Convertible Stock^F3,F1,F2	—	May 12, 2015	C	3,160,905	D	—	—	Common Stock	458,102	I
Series C Convertible Stock^F3,F1,F2	—	May 12, 2015	C	63,356	D	—	—	Common Stock	9,182	I
Series D Convertible Stock^F3,F1,F2	—	May 12, 2015	C	5,045,381	D	—	—	Common Stock	741,830	I
Series D Convertible Stock^F3,F1,F2	—	May 12, 2015	C	101,128	D	—	—	Common Stock	14,868	I

F1All series of Convertible Preferred Stock automatically converted into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and had no expiration date.
F2Reflects the conversion of preferred stock into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis which became effective on May 12, 2015.
F3The shares are held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. (collectively, the "Longitude Funds"). Longitude Capital Partners, LLC is the general partner of the Longitude Funds. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of Longitude Capital Partners, LLC and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons. David Hirsch is a member of Longitude Capital Partners, LLC. Dr. Hirsch disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.